ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a report released on Wednesday.
A number of other analysts have also weighed in on the company. Canaccord Genuity set a $75.00 price objective on ANI Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, December 9th. TheStreet raised ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Thursday, November 16th. Finally, Zacks Investment Research raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price objective on the stock in a research report on Tuesday, November 7th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. ANI Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $70.50.
ANI Pharmaceuticals (NASDAQ:ANIP) traded down $1.98 during trading on Wednesday, hitting $63.49. The stock had a trading volume of 123,532 shares, compared to its average volume of 136,789. ANI Pharmaceuticals has a 1-year low of $42.23 and a 1-year high of $74.70. The company has a quick ratio of 2.39, a current ratio of 3.45 and a debt-to-equity ratio of 0.83. The stock has a market capitalization of $772.13, a price-to-earnings ratio of 19.78 and a beta of 2.91.
Several hedge funds have recently modified their holdings of the stock. GSA Capital Partners LLP acquired a new position in shares of ANI Pharmaceuticals during the third quarter worth $530,000. Dana Investment Advisors Inc. grew its stake in shares of ANI Pharmaceuticals by 4.2% during the third quarter. Dana Investment Advisors Inc. now owns 44,505 shares of the specialty pharmaceutical company’s stock worth $2,336,000 after purchasing an additional 1,785 shares in the last quarter. Violich Capital Management Inc. acquired a new position in shares of ANI Pharmaceuticals during the third quarter worth $217,000. Stifel Financial Corp acquired a new position in shares of ANI Pharmaceuticals during the third quarter worth $349,000. Finally, Skandinaviska Enskilda Banken AB publ grew its stake in shares of ANI Pharmaceuticals by 85.5% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 54,900 shares of the specialty pharmaceutical company’s stock worth $2,882,000 after purchasing an additional 25,300 shares in the last quarter. Hedge funds and other institutional investors own 55.05% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/12/20/ani-pharmaceuticals-anip-cut-to-hold-at-valuengine.html.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.